Understanding Astatine from Cyclotron Synthesis — The Rarest Naturally Occurring Element

Dale Corson, Kenneth MacKenzie, and Emilio Segrè synthesized astatine in 1940 at the University of California, Berkeley, by bombarding bismuth-209 with alpha particles in a cyclotron to produce astatine-211. The name comes from the Greek 'astatos' (unstable). Mendeleev had predicted element 85 as 'eka-iodine' in 1871. Several false claims preceded its synthesis, including 'alabamine' and 'dakin'. Astatine was the second element Segrè helped discover, after technetium in 1937.

At any given moment, the entire Earth's crust contains approximately 25 grams of astatine — making it the rarest naturally occurring element. It exists only as fleeting intermediates in the uranium and thorium decay chains. Astatine-219 (in the actinium series) has a half-life of 56 seconds, while At-218 (in the radium series) has a half-life of just 1.5 seconds. No one has ever seen astatine with the naked eye. Its bulk properties are predicted entirely from periodic trends and relativistic calculations.

Astatine-211 (half-life 7.2 hours) is produced by bombarding bismuth-209 with 28 MeV alpha particles in a cyclotron: Bi-209 + He-4 → At-211 + 2n. Only a few cyclotrons worldwide produce At-211 in quantities useful for research — typically micrograms per run. The target is a thin layer of bismuth metal on an aluminum backing. After irradiation, astatine is separated by dry distillation at 650°C, exploiting its volatility relative to bismuth.

Astatine is the heaviest halogen and shows increasingly metallic character compared to its lighter congeners. Relativistic effects contract its electron orbitals, making At⁻ ions less stable than expected and At⁺ cations more accessible. Astatine forms interhalogen compounds (AtI, AtBr, AtCl) and is coprecipitated with silver astatide (AgAt) — evidence of halide behavior. It also shows some metallic properties, adsorbing onto metallic silver like a metal rather than a halide in some conditions.

Astatine-211 is one of the most promising alpha-emitting isotopes for targeted alpha therapy (TAT) — a precision cancer treatment. At-211 is attached to monoclonal antibodies or small molecules that seek out cancer cells. Each alpha decay deposits 6.8 MeV of energy within 50-80 micrometers — enough to destroy one or two cells while sparing surrounding tissue. Clinical trials are ongoing for glioblastoma, ovarian cancer, leukemia, and thyroid cancer. The 7.2-hour half-life matches clinical infusion timelines.

As a halogen, astatine is concentrated by the thyroid gland — the same mechanism used in iodine-131 therapy for thyroid cancer. Free astatide (At⁻) accumulates in thyroid tissue at rates comparable to iodide. This makes At-211 a candidate for treating thyroid carcinomas that are resistant to iodine-131, since alpha particles are more biologically destructive than the beta particles from I-131. The challenge is preventing astatine from dehalogenating (detaching) from carrier molecules in vivo.

Working with astatine pushes the boundaries of chemistry — experiments are performed with nanogram to microgram quantities where single atoms may be involved. At these concentrations, astatine behavior is influenced by radiolysis (self-destruction from its own radiation), adsorption onto container walls, and the absence of carrier atoms to stabilize chemical species. Every experiment is a race against the 7.2-hour half-life. Astatine chemistry must be performed in lead-shielded hot cells with remote manipulators.

No one has ever accumulated enough astatine to observe bulk properties directly. Based on periodic trends and relativistic quantum calculations, astatine is predicted to be a dark semiconductor or semimetal, likely black in appearance, with a melting point around 302°C and boiling point around 337°C. It would be the densest halogen at approximately 6.2-6.5 g/cm³. These predictions remain untestable because the isotope's radioactivity would vaporize any visible sample through self-heating.

The medical development of At-211 faces a critical supply bottleneck — only a handful of medium-energy cyclotrons worldwide can produce it, and the 7.2-hour half-life prevents stockpiling or long-distance shipping. Current producers include cyclotrons at Duke University, University of Copenhagen, and Osaka University. Expanding clinical trials requires new production facilities within hours of treatment centers. The DOE Isotope Program is funding dedicated At-211 production infrastructure in the United States.

Record astatine's key data: atomic number 85, predicted density ~6.4 g/cm³, predicted melting point ~302°C, heaviest halogen. Astatine is the element that exists more in theory than in matter — predicted since 1871, synthesized in 1940, never seen in bulk, yet now at the frontier of cancer treatment. Targeted alpha therapy with At-211 could transform oncology by delivering lethal radiation to individual cancer cells. The rarest natural element may become one of the most valuable in medicine.